$FATE
FATE THERAPEUTICS INC Stock $fate

$fate Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000104746914002516 Filed on March 17, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013 Q3
Revenue	$0.00	$0.00	$209.0K
YoY Change	-100.0%	-100.0%	-60.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.420M	$1.870M	$1.980M
YoY Change	86.15%	46.09%	130.23%
% of Gross Profit
Research & Development	$4.522M	$3.030M	$3.378M
YoY Change	78.66%	-10.88%	1.9%
% of Gross Profit
Depreciation & Amortization	$123.0K	$130.0K	$140.0K
YoY Change	-21.66%	-18.75%	-6.67%
% of Gross Profit
Operating Expenses	$6.937M	$4.902M	$5.357M
YoY Change	81.22%	4.59%	28.22%
Operating Profit	-$6.937M		-$5.148M
YoY Change	106.7%		41.04%
Interest Expense	$43.00K	-$840.0K	-$930.0K
YoY Change	-57.0%
% of Operating Profit
Other Income/Expense, Net	-$43.00K		-$925.0K
YoY Change	-77.6%		99.78%
Pretax Income	-$6.980M	-$5.740M	-$6.070M
YoY Change	96.62%	37.98%	47.69%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.980M	-$5.739M	-$6.073M
YoY Change	96.73%	38.12%	47.65%
Net Earnings / Revenue			-2905.74%
Basic Earnings Per Share
Diluted Earnings Per Share	-$343.0K	-$299.6K	-$316.8K
COMMON SHARES
Basic Shares Outstanding	20.44M shares	20.36M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q4	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$47.90M	$54.00M	$19.10M
YoY Change	941.3%	493.41%
Cash & Equivalents	$47.88M	$54.04M	$19.08M
Short-Term Investments
Other Short-Term Assets	$400.0K	$600.0K	$300.0K
YoY Change	-33.33%	-14.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$48.26M	$54.65M	$19.39M
YoY Change	810.62%	458.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.264M	$810.0K	$789.0K
YoY Change	26.4%	-30.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$2.743M
YoY Change	0.0%	0.0%
Total Long-Term Assets	$1.386M	$932.0K	$3.654M
YoY Change	26.0%	-27.36%
TOTAL ASSETS
Total Short-Term Assets	$48.26M	$54.65M	$19.39M
Total Long-Term Assets	$1.386M	$932.0K	$3.654M
Total Assets	$49.65M	$55.58M	$23.04M
YoY Change	675.77%	401.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.330M	$682.0K	$3.700M
YoY Change	-16.88%	-44.46%
Accrued Expenses	$1.641M	$2.039M
YoY Change		96.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$3.500M
YoY Change
Long-Term Debt Due	$1.240M	$1.732M	$1.971M
YoY Change	-38.0%	-10.77%
Total Short-Term Liabilities	$4.354M	$4.600M	$9.491M
YoY Change	6.2%	-5.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$250.0K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$100.0K	$100.0K	$3.200M
YoY Change	-88.89%	-87.5%
Total Long-Term Liabilities	$100.0K	$100.0K	$250.0K
YoY Change	-95.24%	-94.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.354M	$4.600M	$9.491M
Total Long-Term Liabilities	$100.0K	$100.0K	$250.0K
Total Liabilities	$4.500M	$4.700M	$9.741M
YoY Change	-27.42%	-28.59%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$20.00K	$20.00K	$1.000K
YoY Change		1900.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$45.18M	$50.85M	-$66.40M
YoY Change
Total Liabilities & Shareholders Equity	$49.65M	$55.58M	$23.04M
YoY Change	675.77%	401.83%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013 Q3
OPERATING ACTIVITIES
Net Income	-$6.980M	-$5.739M	-$6.073M
YoY Change	96.73%	38.12%	47.65%
Depreciation, Depletion And Amortization	$123.0K	$130.0K	$140.0K
YoY Change	-21.66%	-18.75%	-6.67%
Cash From Operating Activities	-$5.260M	-$4.570M	-$3.480M
YoY Change	33.84%	34.81%	25.63%
INVESTING ACTIVITIES
Capital Expenditures	$398.0K	-$150.0K	-$20.00K
YoY Change	5585.71%	-50.0%	-94.29%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$10.00K
YoY Change
Cash From Investing Activities	-$400.0K	-$150.0K	-$20.00K
YoY Change	3900.0%	-50.0%	-94.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$2.000K
YoY Change
Debt Paid & Issued, Net	$500.0K
YoY Change	0.0%
Cash From Financing Activities	-500.0K	39.68M	19.17M
YoY Change	0.0%	442.82%	514.42%
NET CHANGE
Cash From Operating Activities	-5.260M	-4.570M	-3.480M
Cash From Investing Activities	-400.0K	-150.0K	-20.00K
Cash From Financing Activities	-500.0K	39.68M	19.17M
Net Change In Cash	-6.160M	34.96M	15.67M
YoY Change	38.74%	865.75%	-1682553438208000000.0%
FREE CASH FLOW
Cash From Operating Activities	-$5.260M	-$4.570M	-$3.480M
Capital Expenditures	$398.0K	-$150.0K	-$20.00K
Free Cash Flow	-$5.658M	-$4.420M	-$3.460M
YoY Change	43.71%	43.04%	42.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012	fate	Stock Issued During Period Value Technology StockIssuedDuringPeriodValueTechnology	21000	USD
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	11889000	USD
CY2012	fate	Stock Issued During Period Value Exchange Of Debt And Common Stock For Preferred Stock StockIssuedDuringPeriodValueExchangeOfDebtAndCommonStockForPreferredStock	-32000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	155000	USD
CY2011	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	7000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	172000	USD
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	USD
CY2010	fate	Stock Issued During Period Value Technology StockIssuedDuringPeriodValueTechnology	5000	USD
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	-8353000	USD
CY2007Q4	us-gaap	Stockholders Equity StockholdersEquity	-1219000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23000	USD
CY2013	fate	Adjustments To Additional Paid In Capital Repurchase Liability For Unvested Equity Awards AdjustmentsToAdditionalPaidInCapitalRepurchaseLiabilityForUnvestedEquityAwards	49000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1554000	USD
CY2013	fate	Stock Issued During Period Value Technology StockIssuedDuringPeriodValueTechnology	13000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	571000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	40480000	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	56526000	USD
CY2013	fate	Stock Issued During Period Value Conversion Of Convertible Notes Into Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleNotesIntoCommonStock	22076000	USD
CY2013	fate	Stock Issued During Period Value Exchange Of Exchangeable Shares Into Common Stock StockIssuedDuringPeriodValueExchangeOfExchangeableSharesIntoCommonStock	3318000	USD
CY2013	fate	Adjustments To Additional Paid In Capital Reclassification Of Warrant Liability AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability	192000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000	USD
CY2012	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	192000	USD
CY2012	fate	Adjustments To Additional Paid In Capital Repurchase Liability For Unvested Equity Awards AdjustmentsToAdditionalPaidInCapitalRepurchaseLiabilityForUnvestedEquityAwards	-143000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	229000	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-16222000	USD
CY2009	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	USD
CY2009	fate	Stock Issued During Period Value Technology StockIssuedDuringPeriodValueTechnology	17000	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	196000	USD
CY2008	fate	Stock Repurchased Of Founders Stock During Period Value StockRepurchasedOfFoundersStockDuringPeriodValue	2000	USD
CY2008	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18000	USD
CY2008	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2008	fate	Stock Issued During Period Value Technology StockIssuedDuringPeriodValueTechnology	1000	USD
CY2008	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	5000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1224000	USD
	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	0.001
CY2013	fate	Number Of Platforms To Enhance Therapeutic Potential Of Adult Stem Cells NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells	2	item
CY2013	us-gaap	Revenue Recognition Milestone Method Factors RevenueRecognitionMilestoneMethodFactors	(i) persuasive evidence that an agreement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectibility is reasonably assured
CY2013	fate	Shares Attributable To Share Based Payment Arrangements Excluded From Weighted Average Number Of Shares Outstanding SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding	107570	shares
CY2012	fate	Shares Attributable To Share Based Payment Arrangements Excluded From Weighted Average Number Of Shares Outstanding SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding	173772	shares
CY2011	fate	Shares Attributable To Share Based Payment Arrangements Excluded From Weighted Average Number Of Shares Outstanding SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding	303253	shares
CY2013	fate	Stock Issued During Period Shares Technology StockIssuedDuringPeriodSharesTechnology	7692	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1763065	shares
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9101874	shares
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6072766	shares
CY2013Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1750000	USD
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3750000	USD
CY2012Q4	fate	Debt Instrument Discount Non Current DebtInstrumentDiscountNonCurrent	18000	USD
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	1750000	USD
CY2012Q4	us-gaap	Long Term Debt LongTermDebt	3732000	USD
CY2013Q4	fate	Long Term Debt Gross Current LongTermDebtGrossCurrent	1750000	USD
CY2012Q4	fate	Long Term Debt Gross Current LongTermDebtGrossCurrent	2000000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54036000	USD
CY2013Q4	fate	Debt Instrument Discount Current DebtInstrumentDiscountCurrent	18000	USD
CY2012Q4	fate	Debt Instrument Discount Current DebtInstrumentDiscountCurrent	59000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9087000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	615000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	5357000	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	4902000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	3538000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	3824000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	4178000	USD
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.43
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	4687000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-3548000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-5534000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-6073000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-5739000	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-4155000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.92
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.46
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.81
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-3234000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-2737000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-4113000	USD
CY2013Q4	fate	Deferred Tax Assets Section59e Amortization DeferredTaxAssetsSection59eAmortization	12070000	USD
CY2012Q4	fate	Deferred Tax Assets Section59e Amortization DeferredTaxAssetsSection59eAmortization	9766000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	72000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	101000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	880000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	787000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	845000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	706000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13867000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13867000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	495000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11149000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11149000	USD
CY2013Q4	fate	Unrecognized Tax Benefits Resulting In Net Operating Loss And Tax Credit Carryforward UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	5000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16000	USD
CY2009Q1	fate	Defined Contribution Plan Minimum Age Of Employee DefinedContributionPlanMinimumAgeOfEmployee	P21Y
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	472000	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	290000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	209000	USD
CY2012Q1	us-gaap	Sales Revenue Net SalesRevenueNet	418000	USD
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1081000	USD
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	528000	USD
CY2012Q4	us-gaap	Sales Revenue Net SalesRevenueNet	643000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	3828000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	4559000	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.58
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.51
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	11000	USD
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.51
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	590000	USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	672000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2508000	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	13000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3106000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2910000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2296000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1749000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	54651000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	9793000	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	21000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Use of Estimates</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The preparation of the Company's consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company's consolidated financial statements and accompanying notes. The most significant estimates in the Company's consolidated financial statements relate to the valuation of equity awards and clinical trial accruals. Although these estimates are based on the Company's knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></p> </div>
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Concentration of Credit Risk</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</font></p> </div>
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	57000	USD
CY2013Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7666667	shares
CY2013Q4	us-gaap	Share Price SharePrice	6.00
CY2008	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	0.007
CY2013Q4	fate	Stock Issued During Period Shares Conversion Of Convertible Notes Into Common Stock StockIssuedDuringPeriodSharesConversionOfConvertibleNotesIntoCommonStock	3679401	shares
CY2013Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	7229590	shares
CY2013Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	22100000	USD
CY2013Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	3679401	shares
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	300000	USD
CY2013Q4	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	400000	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	230000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1941000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	810000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1161000	USD
CY2013	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	FATE THERAPEUTICS INC
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001434316
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20435676	shares
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013Q4	dei	Entity Public Float EntityPublicFloat	0	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	122000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	122000	USD
CY2013Q4	us-gaap	Assets Assets	55583000	USD
CY2012Q4	us-gaap	Assets Assets	11076000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2039000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1040000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	63000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	53000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	251000	USD
CY2013Q4	fate	Repurchase Liability For Unvested Equity Awards Current RepurchaseLiabilityForUnvestedEquityAwardsCurrent	94000	USD
CY2012Q4	fate	Repurchase Liability For Unvested Equity Awards Current RepurchaseLiabilityForUnvestedEquityAwardsCurrent	143000	USD
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	184000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1732000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4600000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4850000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	135000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	132000	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	110000	USD
CY2012Q4	fate	Exchangeable Share Liability Noncurrent ExchangeableShareLiabilityNoncurrent	551000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1732000	USD
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	56526000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137337000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12789000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	86509000	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	65615000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	50848000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-52825000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55583000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11076000	USD
CY2013Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2011	us-gaap	Operating Expenses OperatingExpenses	14463000	USD
	us-gaap	Operating Expenses OperatingExpenses	87696000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.54
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5896171	shares
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-17675000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-13557000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-13293000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-82685000	USD
CY2012Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2012Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	62200000	shares
CY2013Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2012Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	44967690	shares
CY2012Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	44967690	shares
CY2013Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2013	us-gaap	Contracts Revenue ContractsRevenue	626000	USD
CY2012	us-gaap	Contracts Revenue ContractsRevenue	1268000	USD
CY2011	us-gaap	Contracts Revenue ContractsRevenue	833000	USD
	us-gaap	Contracts Revenue ContractsRevenue	2927000	USD
CY2013	us-gaap	Revenue From Grants RevenueFromGrants	345000	USD
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	1402000	USD
CY2011	us-gaap	Revenue From Grants RevenueFromGrants	337000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	2084000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	971000	USD
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	2670000	USD
CY2011	us-gaap	Sales Revenue Net SalesRevenueNet	1170000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	5011000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1334115	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20434080	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20434080	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1334115	shares
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12007000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11999000	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9858000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56986000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6639000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4228000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4605000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30710000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	18646000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	16227000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	USD
CY2011	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	192000	USD
CY2013	us-gaap	Interest Expense InterestExpense	796000	USD
CY2012	us-gaap	Interest Expense InterestExpense	487000	USD
CY2011	us-gaap	Interest Expense InterestExpense	127000	USD
	us-gaap	Interest Expense InterestExpense	2641000	USD
	us-gaap	Investment Tax Credit InvestmentTaxCredit	-1231000	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-13.06
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1090317	shares
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	709000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1554000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	155000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	172000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2323000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	394000	USD
CY2012	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	84000	USD
CY2011	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	23000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	535000	USD
CY2013	us-gaap	Paid In Kind Interest PaidInKindInterest	147000	USD
CY2012	us-gaap	Paid In Kind Interest PaidInKindInterest	121000	USD
CY2011	us-gaap	Paid In Kind Interest PaidInKindInterest	13000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3219000	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-682000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	1169000	USD
CY2013	us-gaap	Straight Line Rent StraightLineRent	195000	USD
CY2012	us-gaap	Straight Line Rent StraightLineRent	197000	USD
CY2011	us-gaap	Straight Line Rent StraightLineRent	-228000	USD
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-134000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3824000	USD
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-16.16
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	830959	shares
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-20894000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-14239000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-13427000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-86509000	USD
	us-gaap	Straight Line Rent StraightLineRent	-188000	USD
CY2013	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	63000	USD
CY2012	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	83000	USD
CY2011	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	646000	USD
CY2013	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	2421000	USD
CY2012	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	-90000	USD
CY2011	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	5000	USD
	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	2309000	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8000	USD
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-37000	USD
CY2011	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-35000	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-18000	USD
CY2011	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-117000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-135000	USD
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-323000	USD
CY2011	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-9000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-332000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1271000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	405000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-209000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1977000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1578000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	405000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	134000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3847000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15373000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13274000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12145000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-74109000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	244000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	58646000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	60560000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16683000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7107000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	131720000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	44949000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2700000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4838000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	54036000	USD
CY2013	us-gaap	Interest Paid InterestPaid	250000	USD
CY2012	us-gaap	Interest Paid InterestPaid	282000	USD
CY2011	us-gaap	Interest Paid InterestPaid	90000	USD
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-50683000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-37435000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	-21457000	USD
	us-gaap	Interest Paid InterestPaid	930000	USD
CY2013Q3	fate	Lease Term Extended LeaseTermExtended	P2Y
CY2013Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	100000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3661000	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000	USD
CY2011	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	202000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	208000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	122000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-238000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-709000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	200000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3575000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	207000	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	294000	USD
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7000	USD
CY2013	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	40480000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	40480000	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	23736000	USD
CY2011	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1000000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	32236000	USD
CY2011	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3400000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11225000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6387000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	6400000	USD
CY2013	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2000000	USD
CY2012	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	250000	USD
CY2011	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	800000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4650000	USD
CY2012	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	16726000	USD
CY2011	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	3500000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
CY2011	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3800000	USD
CY2013	fate	Minimum Annual Payments To Maintain Licenses MinimumAnnualPaymentsToMaintainLicenses	300000	USD
CY2013Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2011000	USD
CY2013Q4	fate	Long Term Debt Maturities Repayments Interest Included In Payments LongTermDebtMaturitiesRepaymentsInterestIncludedInPayments	-61000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	911000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	943000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	480000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2334000	USD
CY2013Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	2922000	USD
CY2013Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	943000	USD
CY2013Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	480000	USD
CY2013Q4	us-gaap	Contractual Obligation ContractualObligation	4345000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2009	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	4000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	8388000	USD
CY2011	fate	Issuance Of Warrants In Connection With Long Term Debt IssuanceOfWarrantsInConnectionWithLongTermDebt	172000	USD
	fate	Issuance Of Warrants In Connection With Long Term Debt IssuanceOfWarrantsInConnectionWithLongTermDebt	226000	USD
CY2013	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	336000	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	336000	USD
CY2013Q4	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1700000	USD
CY2012	fate	Stock Issued During Period Shares Technology StockIssuedDuringPeriodSharesTechnology	15385	shares
CY2010	fate	Stock Issued During Period Shares Technology StockIssuedDuringPeriodSharesTechnology	3077	shares
CY2009	fate	Stock Issued During Period Shares Technology StockIssuedDuringPeriodSharesTechnology	46923	shares
CY2008	fate	Stock Issued During Period Shares Technology StockIssuedDuringPeriodSharesTechnology	18462	shares
	fate	Stock Issued During Period Shares Technology StockIssuedDuringPeriodSharesTechnology	91539	shares
CY2008Q4	us-gaap	Share Price SharePrice	1
CY2009Q4	us-gaap	Share Price SharePrice	17
CY2010Q4	us-gaap	Share Price SharePrice	5
CY2012Q4	us-gaap	Share Price SharePrice	21
CY2013Q4	us-gaap	Share Price SharePrice	13
CY2013	fate	Business Acquisition Equity Interests Potential Increase In Number Of Shares Achievement Of Certain Preclinical Milestones BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones	76923	shares
CY2013	fate	Business Acquisition Equity Interests Potential Increase In Number Of Shares Achievement Of Certain Clinical Milestones BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones	211538	shares
CY2013	fate	Business Acquisition Equity Interests Potential Increase In Number Of Shares Achievement Of Certain Commercialization Milestones BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones	115381	shares
CY2013Q4	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	400000	USD
CY2013	fate	Adjustment To Additional Paid In Capital Reclassification Of Exchangeable Shares AdjustmentToAdditionalPaidInCapitalReclassificationOfExchangeableShares	3300000	USD
CY2013Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3899433	shares
CY2012Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9737086	shares
CY2013Q4	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	6.00
CY2013Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	46000000	USD
CY2013Q4	fate	Net Proceeds From Issuance Initial Public Offering NetProceedsFromIssuanceInitialPublicOffering	40500000	USD
CY2013Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	68360186	shares
CY2013Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	44967690	shares
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1554000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	155000	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	172000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2323000	USD
CY2013Q4	fate	Common Stock Issuable Upon Redemption Of Exchangeable Shares CommonStockIssuableUponRedemptionOfExchangeableShares	480763	shares
CY2013Q4	fate	Class Of Warrant Or Right Warrants Issued To Purchase Shares Of Convertible Preferred Stock Converted ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted	230000	shares
CY2013Q4	fate	Class Of Warrant Or Right Warrants Issued To Purchase Shares Of Common Stock On Conversion ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion	36074	shares
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	682000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1228000	USD
CY2013	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1679000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1679000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	56526000	USD
	fate	Stock Issued During Period Value Conversion Of Convertible Notes Into Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleNotesIntoCommonStock	22076000	USD
	fate	Stock Issued During Period Value Exchange Of Exchangeable Shares Into Common Stock StockIssuedDuringPeriodValueExchangeOfExchangeableSharesIntoCommonStock	3318000	USD
	fate	Adjustments To Additional Paid In Capital Reclassification Of Warrant Liability AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability	192000	USD
CY2013	fate	Long Term Debt Maturities Additional Payments Due On Maturity LongTermDebtMaturitiesAdditionalPaymentsDueOnMaturity	-200000	USD
CY2013	fate	Initial Fair Value And Adjustment Of Exchangeable Shares InitialFairValueAndAdjustmentOfExchangeableShares	2767000	USD
CY2012	fate	Initial Fair Value And Adjustment Of Exchangeable Shares InitialFairValueAndAdjustmentOfExchangeableShares	-12000	USD
CY2011	fate	Initial Fair Value And Adjustment Of Exchangeable Shares InitialFairValueAndAdjustmentOfExchangeableShares	356000	USD
	fate	Initial Fair Value And Adjustment Of Exchangeable Shares InitialFairValueAndAdjustmentOfExchangeableShares	3318000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7104000	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4842000	USD
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4540000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1011000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-777000	USD
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-742000	USD
CY2013	fate	Income Tax Reconciliation Permanent Tax Differences IncomeTaxReconciliationPermanentTaxDifferences	755000	USD
CY2012	fate	Income Tax Reconciliation Permanent Tax Differences IncomeTaxReconciliationPermanentTaxDifferences	113000	USD
CY2011	fate	Income Tax Reconciliation Permanent Tax Differences IncomeTaxReconciliationPermanentTaxDifferences	135000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	161000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	36000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	621000	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	243000	USD
CY2011	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	515000	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-8000	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	207000	USD
CY2011	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	5000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7828000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5506000	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5657000	USD

Files In Submission

Name	View Source	Status
0001047469-14-002516-index-headers.html	Edgar Link	pending
0001047469-14-002516-index.html	Edgar Link	pending
0001047469-14-002516.txt	Edgar Link	pending
0001047469-14-002516-xbrl.zip	Edgar Link	pending
a2219013z10-k.htm	Edgar Link	pending
a2219013zex-14_1.htm	Edgar Link	pending
a2219013zex-23_1.htm	Edgar Link	pending
a2219013zex-31_1.htm	Edgar Link	pending
a2219013zex-31_2.htm	Edgar Link	pending
a2219013zex-32_1.htm	Edgar Link	pending
a2219013zex-32_2.htm	Edgar Link	pending
fate-20131231.xml	Edgar Link	completed
fate-20131231.xsd	Edgar Link	pending
fate-20131231_cal.xml	Edgar Link	unprocessable
fate-20131231_def.xml	Edgar Link	unprocessable
fate-20131231_lab.xml	Edgar Link	unprocessable
fate-20131231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g186275.jpg	Edgar Link	pending
g288298.jpg	Edgar Link	pending
g292839.jpg	Edgar Link	pending
g298393.jpg	Edgar Link	pending
g303294.jpg	Edgar Link	pending
g346524.jpg	Edgar Link	pending
g346884.jpg	Edgar Link	pending
g474687.jpg	Edgar Link	pending
g656157.jpg	Edgar Link	pending
g756771.jpg	Edgar Link	pending
g780196.jpg	Edgar Link	pending
g87868.jpg	Edgar Link	pending
g897059.jpg	Edgar Link	pending
g907110.jpg	Edgar Link	pending
g916951.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FATE
FATE THERAPEUTICS INC Stock $fate

2014 Q1 Form 10-K Financial Statement

#000104746914002516 Filed on March 17, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE FATE THERAPEUTICS INC Stock $fate

2014 Q1 Form 10-K Financial Statement

#000104746914002516 Filed on March 17, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE
FATE THERAPEUTICS INC Stock $fate